Shipping services continue despite COVID-19 outbreak ! Click here to view COVID-19 related products

PF-4708671

For research use only.

Licensed and Manufactured by Pfizer Catalog No.S2163

32 publications

PF-4708671 Chemical Structure

CAS No. 1255517-76-0

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. PF-4708671 induces autophagy. First S6K1-specific inhibitor to be reported.

Size Price Stock Quantity  
10mM (1mL in DMSO) RMB 1574.66 In stock
RMB 876.33 In stock
RMB 1179.06 In stock
RMB 2197.72 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's PF-4708671 has been cited by 32 publications

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Description PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. PF-4708671 induces autophagy. First S6K1-specific inhibitor to be reported.
Targets
p70 S6K1 [1]
(Cell-free assay)
160 nM
In vitro

PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BHT-101 NX3vSnZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHFcmlKSzVyPUCuPFIxOjRizszN NG[wdHFUSU6JRWK=
UACC-893 NXeyTYIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTVwMUm4PFYh|ryP NWPEcJF4W0GQR1XS
A427 M17Ld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3pe3VKSzVyPUWuO|I2PjdizszN Ml[xV2FPT0WU
OCUB-M MoC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13ZV2lEPTB;Nj62OlExOiEQvF2= Mn\nV2FPT0WU
SW684 M3HodGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXxXpZSUUN3ME23MlUzOjZ6IN88US=> M2G1TXNCVkeHUh?=
SK-LMS-1 NGHEdVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITRWYRKSzVyPUmuNFE{ODJizszN MlqzV2FPT0WU
CP50-MEL-B MmLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTzTWM2OD17LkOwOFE6KM7:TR?= NXTydnVVW0GQR1XS
NCI-H1651 NIKzV2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmj3TWM2OD1zMD6wNlc3KM7:TR?= M3j5RXNCVkeHUh?=
ABC-1 NIDwRWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDpcWE4UUN3ME2xNE4yODN5IN88US=> MlvCV2FPT0WU
OE19 MnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjDcVZKSzVyPUGwMlE4OzNizszN NYXCNVROW0GQR1XS
DSH1 NFPSS5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\VTWM2OD1zMD64PFc6KM7:TR?= NG\Dd41USU6JRWK=
SW13 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTFzLkmzNVkh|ryP MnLhV2FPT0WU
MDA-MB-453 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jlb2lEPTB;MUKuNVYxOyEQvF2= NHPpbmxUSU6JRWK=
647-V MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3m0ZmlEPTB;MUKuN|U5OiEQvF2= M4HabHNCVkeHUh?=
NCI-H2342 MonOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTF{LkO5PVUh|ryP Mn;DV2FPT0WU
LB2241-RCC M4O5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHzR3NKSzVyPUGyMlU4PzlizszN MmfFV2FPT0WU
UACC-257 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTESWJKSzVyPUGzMlQ1PTNizszN NUDHRmE3W0GQR1XS
NCI-H661 NGPWTmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\5W2tMUUN3ME2xN{43PDR7IN88US=> NGfsVmVUSU6JRWK=
FADU MkPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTPNnpKSzVyPUGzMlY6QTJizszN NX[zV202W0GQR1XS
A2780 NVTyfItpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmf6TWM2OD1zMz64NFQyKM7:TR?= MljYV2FPT0WU
NCI-H1793 M3K2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK0V|RKSzVyPUG0MlQxQDVizszN NFjpXm9USU6JRWK=
TE-8 MljWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\lc5JKSzVyPUG1MlM1PjVizszN M2\DS3NCVkeHUh?=
HGC-27 NXzs[ZpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmr0TWM2OD1zNj6xOlQ1KM7:TR?= NWTqXY5MW0GQR1XS
MMAC-SF NF7qTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;0VnpKSzVyPUG3MlM4OjdizszN M3jyZnNCVkeHUh?=
Calu-6 MmHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvQTWM2OD1zOD6xOVE{KM7:TR?= M4LBS3NCVkeHUh?=
HUTU-80 NXi2[5djT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTF6LkO5OVkh|ryP Mk\RV2FPT0WU
SAS MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLrXJA4UUN3ME2xPE43PDV3IN88US=> NV[wVGo4W0GQR1XS
IST-MES1 NFrxc2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPLT2ZKSzVyPUG4MlY2ODhizszN NE\zbmpUSU6JRWK=
C3A MkDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnhem12UUN3ME2xPE44QTF7IN88US=> NYe3dZlqW0GQR1XS
ES3 NYPOfYVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzsWmZKSzVyPUG4Mlg{PjRizszN NGnMfI9USU6JRWK=
HSC-2 M1ntRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTF7Lk[1OFEh|ryP NW\Ob2VsW0GQR1XS
T47D NF7VRoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTJyLkG0PFUh|ryP NGTyS4dUSU6JRWK=
EW-7 Ml31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfYTWM2OD1{MD64OVg5KM7:TR?= MnXHV2FPT0WU
LN-405 NWn5SVFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnO3TWM2OD1{MD64PVY2KM7:TR?= NGTWcllUSU6JRWK=
U031 M2HicGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTJzLkS4NFIh|ryP NIX0c3FUSU6JRWK=
A549 MmP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY[3RZZMUUN3ME2yNU45PDlzIN88US=> Ml;JV2FPT0WU
RMG-I MkGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfHRoNnUUN3ME2yNk4zPjZ6IN88US=> M3rESXNCVkeHUh?=
BT-474 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrONGFGUUN3ME2yNk43PTVzIN88US=> M1rNcXNCVkeHUh?=
NB69 NHPNUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoGxTWM2OD1{Mz6xOVIh|ryP M{[5fHNCVkeHUh?=
NB7 Ml3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDnTWM2OD1{ND6xPFgh|ryP NXPET2NlW0GQR1XS
HCC1569 M{TBSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTJ2Lk[xNlUh|ryP NWHQdFh4W0GQR1XS
MEL-JUSO NXHSXIlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3sTWM2OD1{ND62PVA5KM7:TR?= Mk[0V2FPT0WU
MDA-MB-175-VII NVyxUodiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;keFlKSzVyPUK1MlI2OTdizszN NGLwb|ZUSU6JRWK=
HCC1419 NGX5VFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;zdGlEPTB;MkWuOlAxOyEQvF2= M3TTZXNCVkeHUh?=
Ca9-22 NEK4T5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4W2XWlEPTB;MkWuOlQ{OiEQvF2= NEnTOY1USU6JRWK=
KGN Mk\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTJ3Lke1OFch|ryP NFvFZWlUSU6JRWK=
LB373-MEL-D NFnyXmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TObmlEPTB;Mk[uNVk{QCEQvF2= NYr4[Hk5W0GQR1XS
NCI-H1755 M4HsRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTJ4Lki4OFEh|ryP NYnUVJltW0GQR1XS
D-423MG M4ruXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrxSZpKSzVyPUK3MlA4OTVizszN M{PtVXNCVkeHUh?=
DK-MG NEHwdYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4[4TGlEPTB;MkiuO|g1PiEQvF2= NX\zXWpMW0GQR1XS
NCI-H1623 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjrNIJKSzVyPUK4Mlg{PDJizszN NY[zV3M6W0GQR1XS
KU-19-19 MmfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jZUWlEPTB;MkiuPVk2KM7:TR?= NELaXVBUSU6JRWK=
C-33-A M2fpN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XkO2lEPTB;MkmuNlE6QCEQvF2= M1PiZnNCVkeHUh?=
SCC-4 M3fEZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\x[2lEPTB;M{CuN|M2PCEQvF2= NEjFWFRUSU6JRWK=
MG-63 NXOwN|l2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jScWlEPTB;M{CuOVk6PCEQvF2= NYnpOYc6W0GQR1XS
LNCaP-Clone-FGC NV3yNmtIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHUWYpKSzVyPUOxMlQ6OjFizszN MmTBV2FPT0WU
CAPAN-1 NVi4XoxmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTNzLkWyPFYh|ryP M3L5WXNCVkeHUh?=
GI-ME-N MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4D1cmlEPTB;M{GuOVM2OyEQvF2= MkThV2FPT0WU
RERF-LC-MS NUfCOopxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjYTWM2OD1|Mj62O|Q4KM7:TR?= NInDUJVUSU6JRWK=
KLE MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofJTWM2OD1|Mz60N|M1KM7:TR?= MlTGV2FPT0WU
KNS-81-FD M{PoSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LpfmlEPTB;M{OuOVAxQCEQvF2= NGTR[I5USU6JRWK=
DOK MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTN2Lk[2NVIh|ryP NHnCUHRUSU6JRWK=
ACHN Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTN3LkG1PFgh|ryP MlzUV2FPT0WU
KYSE-520 NIHxfWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXP5NJpJUUN3ME2zOU4zOzZzIN88US=> NG\CbZBUSU6JRWK=
SBC-5 M3vrU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzie3VKSzVyPUO1MlUyOTZizszN MkDUV2FPT0WU
NCI-H28 NUHjVHhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTN3Lk[2PVUh|ryP M1LESXNCVkeHUh?=
ES7 NIG3c4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXP3UJF7UUN3ME2zOk4zOjR7IN88US=> NInxZVFUSU6JRWK=
A172 NVL5R3N[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjjVI17UUN3ME2zOk41OTh5IN88US=> NWTPWVBvW0GQR1XS
UM-UC-3 M4e3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjGTWM2OD1|Nz64O|Q3KM7:TR?= MnHBV2FPT0WU
LXF-289 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHoTWM2OD1|OD6wNFQ4KM7:TR?= MmXBV2FPT0WU
KP-4 NU\VbJdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4j3e2lEPTB;M{iuOFc{QSEQvF2= MVnTRW5ITVJ?
TE-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjBTWM2OD1|OT62OVg6KM7:TR?= Ml\HV2FPT0WU
G-402 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXTWY5KSzVyPUSwMlA3OSEQvF2= NW\3T3d1W0GQR1XS
786-0 M4\lU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTRyLkmwPVYh|ryP MkmxV2FPT0WU
K5 NFXIRlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHvTmNDUUN3ME20NU4{Pjh4IN88US=> M{HESHNCVkeHUh?=
SK-N-DZ M2mxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlf6TWM2OD12MT6zPFI{KM7:TR?= M37NWXNCVkeHUh?=
OVCAR-4 NVTTWXBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mli0TWM2OD12MT63OVY5KM7:TR?= M1rlfHNCVkeHUh?=
T84 NIHGb|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\CNoFKSzVyPUSyMlEzPjNizszN NInybZFUSU6JRWK=
GCIY NU\nT5E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvEWWJKSzVyPUSzMlA5ODNizszN Mm\SV2FPT0WU
BB49-HNC Mn\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTR|LkOzOFgh|ryP MkjhV2FPT0WU
SNU-C2B NVzGXmkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInXZYtKSzVyPUSzMlY1OzZizszN M{L2OnNCVkeHUh?=
TE-6 NVj3XlRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnmSWdsUUN3ME20N{45QDl2IN88US=> M2GxS3NCVkeHUh?=
23132-87 NXjtbZVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[5TWM2OD12ND6yPVc5KM7:TR?= M2PhOXNCVkeHUh?=
DMS-53 Mn;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\pSXhvUUN3ME20OE4{Ozh2IN88US=> MX\TRW5ITVJ?
ONS-76 M4XYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jjS2lEPTB;NESuO|Y3OSEQvF2= MkLLV2FPT0WU
DMS-273 M3T2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1j0cWlEPTB;NESuPVQ{KM7:TR?= M4\hb3NCVkeHUh?=
COLO-824 MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTR3Lki3O|Uh|ryP NVXPV2VUW0GQR1XS
DMS-114 M3K1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LC[GlEPTB;NEWuPFkzPyEQvF2= MnPQV2FPT0WU
YKG-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTsTWM2OD12Nj6wN|U2KM7:TR?= NYj3XZdKW0GQR1XS
RH-18 NXO1dJdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVK1NodqUUN3ME20Ok4{PzN|IN88US=> MWDTRW5ITVJ?
NCI-H1355 NEHLdIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7ZbIpFUUN3ME20Ok43OThizszN NFvSRoxUSU6JRWK=
NCI-H2170 M{HieWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTR5Lke1PFQh|ryP NEH1V2FUSU6JRWK=
OC-314 NWm0WnNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmO0TWM2OD12Nz64OFc5KM7:TR?= NGfh[JVUSU6JRWK=
NCI-H2030 NGT3OY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrwbY5KSzVyPUS3Mlg6ODZizszN M37ZcHNCVkeHUh?=
22RV1 M4jXUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjZTWM2OD12Nz65NFE2KM7:TR?= NFvzRoZUSU6JRWK=
G-401 NVXifJNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL5TWM2OD12OD60OFE2KM7:TR?= MWrTRW5ITVJ?
YAPC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3ncpJGUUN3ME20PU45ODd|IN88US=> MoO5V2FPT0WU
SW1573 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TOdGlEPTB;NUCuNlQ{PSEQvF2= NHX0N|RUSU6JRWK=
COLO-792 M3ruRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULwdmMzUUN3ME21NE43OjN5IN88US=> MlvwV2FPT0WU
KNS-62 M{mxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTpTWM2OD13MD63OVA5KM7:TR?= NEDjOopUSU6JRWK=
NB5 MlW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTVzLkS1NFkh|ryP MUfTRW5ITVJ?
CP66-MEL M1XZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX30W3loUUN3ME21NU43PDB6IN88US=> Ml:1V2FPT0WU
CaR-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr4W5JKUUN3ME21Nk4xPjB4IN88US=> NYrmfFh7W0GQR1XS
CAL-54 M2\YbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXCRWhRUUN3ME21Nk4yOTB{IN88US=> MXTTRW5ITVJ?
8305C NV3ie2E3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHaTWM2OD13Mj6zNVUh|ryP NHv2b5BUSU6JRWK=
Calu-3 NFqyTZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nrTWlEPTB;NUKuN|c{OyEQvF2= M{nx[XNCVkeHUh?=
AU565 NHjtO4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELOVppKSzVyPUWyMlU2ODlizszN NFnkVlJUSU6JRWK=
CW-2 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XwWWlEPTB;NUKuPFY2PCEQvF2= M2DNSHNCVkeHUh?=
BEN NIHzdpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH63coNKSzVyPUWzMlc5PjJizszN M3S4[nNCVkeHUh?=
NCI-H1975 NVjSR2NRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHhPVFKUUN3ME21N{45QTZ4IN88US=> M2PBd3NCVkeHUh?=
HCT-116 NX\vO3dxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlO2TWM2OD13ND6wN|I4KM7:TR?= MVPTRW5ITVJ?
SH-4 M3HtZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjtTWM2OD13ND6xN|gh|ryP M3XPdHNCVkeHUh?=
NCI-H1693 Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfTPHlKSzVyPUW0MlIyODNizszN MofJV2FPT0WU
BPH-1 NW\1d3VCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPCNJZKSzVyPUW1MlI5QTJizszN MWLTRW5ITVJ?
CAMA-1 NYjPco56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF20VFVKSzVyPUW1MlgyOTZizszN MXzTRW5ITVJ?
A388 MkjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWWwTJNOUUN3ME21Ok4xQTh3IN88US=> MVvTRW5ITVJ?
C2BBe1 MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTV4LkK2N|Qh|ryP M{PXUHNCVkeHUh?=
GAMG NVOyU4NZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTaTWFnUUN3ME21Ok42QTV3IN88US=> MW\TRW5ITVJ?
MKN28 NGnqbXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnGcHBSUUN3ME21Ok45ODF|IN88US=> MWDTRW5ITVJ?
VA-ES-BJ MkPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTV4Lki3OFUh|ryP MVTTRW5ITVJ?
HuCCT1 NVe4W|d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXKcWh4UUN3ME21O{4xPDl{IN88US=> MWjTRW5ITVJ?
BFTC-905 M{jBSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHDTWM2OD13Nz6yPFk5KM7:TR?= Mki4V2FPT0WU
LS-123 NHnyN5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zSU2lEPTB;NUeuOVY3QCEQvF2= MU\TRW5ITVJ?
LB996-RCC NHfZUllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\vc3E{UUN3ME21PE4xOjh5IN88US=> MmnRV2FPT0WU
NCI-H1048 M4TrVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH2xOmFKSzVyPUW4MlIyQDhizszN NI\MZYhUSU6JRWK=
COR-L105 MoLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TuS2lEPTB;NUiuO|M{PyEQvF2= NFLrVppUSU6JRWK=
OVCAR-8 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jtU2lEPTB;NUmuNVcyPiEQvF2= NGXIR3FUSU6JRWK=
SK-N-FI NX\6OWdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjyTWM2OD13OT6zNlA4KM7:TR?= NVOzeIw6W0GQR1XS
MES-SA M1nGOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLu[XJLUUN3ME21PU41PTB7IN88US=> NFe2[5RUSU6JRWK=
SCC-9 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGn5TWhKSzVyPUW5MlQ4PTNizszN NULxTIhZW0GQR1XS
EFO-27 MojIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3noUGlEPTB;NUmuPVQ{KM7:TR?= NFzseHNUSU6JRWK=
GT3TKB M{XBTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDOTWM2OD14MD62NFQ5KM7:TR?= NEC1bo5USU6JRWK=
HCC38 NXTWTnZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTZzLkSzO|kh|ryP M4r1PHNCVkeHUh?=
MLMA NIHXN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTZzLk[xOlMh|ryP NUPOOFVFW0GQR1XS
D-566MG NEK5OWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlT2TWM2OD14Mz61NlI1KM7:TR?= NX;ReFROW0GQR1XS
SF295 M3TyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTZ|Lk[2OVUh|ryP MWjTRW5ITVJ?
ES4 NV;ZPYRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrqe|BKSzVyPU[0MlQ4OTlizszN M3XxR3NCVkeHUh?=
CAKI-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrLRWFKSzVyPU[0MlU4OjFizszN MlS0V2FPT0WU
OAW-28 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTZ2Lkm2OFch|ryP NXP2[4FsW0GQR1XS
NCI-H460 NHjpcHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\rb2FuUUN3ME22OU4xQDl5IN88US=> MV3TRW5ITVJ?
JAR NXTiTlhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPTV3NHUUN3ME22OU42PTF4IN88US=> MoDhV2FPT0WU
SNU-449 MkT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXkNIpNUUN3ME22OU44PjF4IN88US=> MWrTRW5ITVJ?
D-392MG MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHlTWM2OD14NT65OFM1KM7:TR?= MWLTRW5ITVJ?
EW-22 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrYfXlzUUN3ME22Ok4{QTVizszN MmfTV2FPT0WU
GCT MnzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2C2b2lEPTB;NkeuNFQ1OyEQvF2= NXriZ45SW0GQR1XS
NOS-1 M{PRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLQZWhKSzVyPU[3MlY5PjdizszN M{jZOHNCVkeHUh?=
RH-1 MmO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTZ6LkW1OVkh|ryP M1nX[XNCVkeHUh?=
HuH-7 NEf1OmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkCzTWM2OD14OT6xNFAzKM7:TR?= MVHTRW5ITVJ?
NUGC-3 NV;Zc4JLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTdyLkm2OFQh|ryP M3vlfXNCVkeHUh?=
IST-SL1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTdzLkKzNlQh|ryP NHLTZ3FUSU6JRWK=
SHP-77 NXXweJEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTd{LkGxPUDPxE1? M2DQfHNCVkeHUh?=
SW1116 NXvyTpdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlOyTWM2OD15Mj6xOFA4KM7:TR?= NWq1N5p{W0GQR1XS
LK-2 MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTd{Lki2NVIh|ryP M3Ho[nNCVkeHUh?=
U-2-OS NXfmbYlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTd|LkG4Nlgh|ryP MYLTRW5ITVJ?
KYSE-150 NIjST5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PI[2lEPTB;N{OuOlEyQCEQvF2= Mnr2V2FPT0WU
U251 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXzdHlnUUN3ME23N{45OTZ6IN88US=> MWDTRW5ITVJ?
HT-1080 MnnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTd2LkK1O|Qh|ryP NGDHdpRUSU6JRWK=
NCI-H1437 M1i1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXISYR3UUN3ME23OE43OzJ4IN88US=> NXm0NHBqW0GQR1XS
HPAF-II M{HqS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTd2Lk[0NVUh|ryP MWjTRW5ITVJ?
Becker NGrWVpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;tTWM2OD15NT6xNVA2KM7:TR?= MoLsV2FPT0WU
PANC-10-05 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[2c|hKSzVyPUe1MlI5PjVizszN MmPMV2FPT0WU
TYK-nu NXPNSWhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTd3LkOxNFIh|ryP NXXlXod2W0GQR1XS
SKG-IIIa M3SwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\XVYdDUUN3ME23OU4{OzRzIN88US=> NIjKVJdUSU6JRWK=
NCI-H1993 Mn;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;mRWlEPTB;N{WuO|M6PyEQvF2= NVO3Z41wW0GQR1XS
S-117 NIDWZnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jU[GlEPTB;N{WuO|U2KM7:TR?= NF\q[lBUSU6JRWK=
HuO9 M1PHTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInOPXlKSzVyPUe2MlAxPDhizszN MnziV2FPT0WU
CAL-51 Mo[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFO3dGFKSzVyPUe2MlExODZizszN Mn3IV2FPT0WU
BT-20 Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPvVnV3UUN3ME23Ok4zOTZ6IN88US=> Ml\PV2FPT0WU
LB831-BLC Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\2PYtKSzVyPUe2MlMzOTdizszN M2X0PHNCVkeHUh?=
LB1047-RCC M3;0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3S3dWlEPTB;N{[uO|YyQSEQvF2= MkfvV2FPT0WU
ES8 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXhTWM2OD15OD6wNFc{KM7:TR?= MWDTRW5ITVJ?
UMC-11 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnY[IYxUUN3ME23PE4xQDh2IN88US=> Ml\nV2FPT0WU
NCI-H226 M3zEW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\XSZhxUUN3ME23PE4yOzF3IN88US=> NVPEV5U2W0GQR1XS
IGROV-1 M3HyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fU[2lEPTB;N{iuOVU2KM7:TR?= MkLEV2FPT0WU
BHY NEXZNolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrjTWM2OD15OT61PVYh|ryP MkTwV2FPT0WU
MKN45 NV;KWWhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLSTWM2OD16MD6zNVc1KM7:TR?= M3n0U3NCVkeHUh?=
IA-LM MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zldWlEPTB;OECuN|UyOSEQvF2= M2TiOHNCVkeHUh?=
WM-115 NGfxe3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLNXpZKSzVyPUixMlQyOTRizszN NVvZepFYW0GQR1XS
VMRC-RCZ MlrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\6TWM2OD16MT60OFI2KM7:TR?= M2TZW3NCVkeHUh?=
NCI-H2291 MoHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfxNIQ6UUN3ME24NU43QDR{IN88US=> MXPTRW5ITVJ?
MCF7 MkLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTh|LkK4PVch|ryP NVfqbGF6W0GQR1XS
639-V NYXPeYUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2W1UmlEPTB;OESuOlEzQSEQvF2= NXPtZ5MzW0GQR1XS
RT4 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYCxclBkUUN3ME24OU4zPDB|IN88US=> MnHZV2FPT0WU
NCI-H2405 Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzaOZB3UUN3ME24OU4zQTl5IN88US=> NWf3N5ZDW0GQR1XS
CAL-33 MlXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnneXRKSzVyPUi1MlY{OTVizszN M1n6eXNCVkeHUh?=
BT-549 M1HrS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHDTWM2OD16NT65N|gzKM7:TR?= NF7HR|JUSU6JRWK=
HT-1197 NUT6VGJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnHOYw5UUN3ME24PE4yODd5IN88US=> M1fQO3NCVkeHUh?=
G-361 MoXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXv2e5pUUUN3ME24PE4yPDd2IN88US=> M4DRNnNCVkeHUh?=
LS-411N MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzDTWM2OD16OT6zN|g5KM7:TR?= MULTRW5ITVJ?
HT-144 NXzvNoNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\nXWlEPTB;OEmuOVk6OiEQvF2= NUfkOWNiW0GQR1XS
DJM-1 MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTh7Lki4OFUh|ryP MVnTRW5ITVJ?
CAL-12T NXvDTnN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTuVohKSzVyPUmwMlc5QTVizszN M2\UcnNCVkeHUh?=
MKN7 NEPkb3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDRTWM2OD17MT6zOVUyKM7:TR?= Mmf0V2FPT0WU
HuP-T3 NEXWfI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHmWJFFUUN3ME25Ok4yODB2IN88US=> NEm5XohUSU6JRWK=
SK-MG-1 MoDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTl4LkGzOFgh|ryP MmDIV2FPT0WU
NCI-H2347 NH;FUoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXy1fHUzUUN3ME25PE4yODR{IN88US=> MojPV2FPT0WU
SW872 NUfOTHMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrqNHZKSzVyPUGwNE41PTZizszN M3v6R3NCVkeHUh?=
COLO-829 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rPWWlEPTB;MUCwMlU2OyEQvF2= M1n4ZXNCVkeHUh?=
MC-IXC MornS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTFyMD62NVUh|ryP MnniV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pS6 / S6 / pS6K / S6K1 / pAKT / AKT ; 

PubMed: 28626016     


Western blot of cell lysates from neurons treated with PF-4708671, rapamycin, and Torin-2, individually or in combination for the indicated times.

p-mTOR / mTOR / p-p70S6K / p70S6K ; 

PubMed: 30423811     


As determined using Western blotting, the phospho-p70S6K (p-p70S6K) inhibitor (PF-4708671) reduced the expression of phospho-mTOR (p-mTOR) and p-p70S6K in SCC-4 and SCC-25 cells. SCC-4 and SCC-25 cells were not treated as negative control (NC) or treated with 20 µM PF-4708671 for 6 h (6 h), 12 h (12 h), 18 h (18 h), 1 day (1 d), 2 days (2 d), and 3 days (3 d). Western blot analysis was performed to examine the expression levels of p-mTOR, mTOR, p-p70S6K, p70S6K, and β-actin.

28626016 30423811
Growth inhibition assay
Cell viability; 

PubMed: 30423811     


Inhibitory effects of various doses (0.5, 1, 2, 5, 10, 20, and 40 µM) of PF-4708671 on SCC-4 (B) and SCC-25 (C) cells were assessed using MTT assay after 72 h of treatment. Data presented are the mean and standard error of the mean of three independent experiments. * p < 0.05, ** p < 0.01, and *** p < 0.001 indicate the statistical significance of differences between cells with and without treatment. t (red ** and *** for SCC-4 and blue *, ** and *** for SCC-25).

30423811

Protocol

Solubility (25°C)

In vitro DMSO 30 mg/mL (76.84 mM)
Ethanol 8 mg/mL (20.49 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 390.41
Formula

C19H21F3N6

CAS No. 1255517-76-0
Storage powder
in solvent
Synonyms N/A
Smiles CCC1=CN=CN=C1N2CCN(CC2)CC3=NC4=C(N3)C=C(C=C4)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Whether the in vivo formula "30% PEG400+0.5% Tween80+5% Propylene glycol" for S2163 is suitable for i.p. or not?

  • Answer:

    The formula "30% PEG400+0.5% Tween80+5% Propylene glycol" on our website is an oral one. It is a suspension.

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products

Tags: buy PF-4708671 | PF-4708671 supplier | purchase PF-4708671 | PF-4708671 cost | PF-4708671 manufacturer | order PF-4708671 | PF-4708671 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID